6794 Stock Overview
Engages in the research and development of stem cell drugs, cell therapy technology, and regenerative medical services in Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
UnicoCell Biomed Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$74.40 |
| 52 Week High | NT$91.00 |
| 52 Week Low | NT$68.00 |
| Beta | -0.33 |
| 11 Month Change | -2.11% |
| 3 Month Change | -10.25% |
| 1 Year Change | -13.19% |
| 33 Year Change | 80.15% |
| 5 Year Change | n/a |
| Change since IPO | 61.74% |
Recent News & Updates
Shareholder Returns
| 6794 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 2.9% | -3.1% | -0.8% |
| 1Y | -13.2% | 2.0% | 29.0% |
Return vs Industry: 6794 underperformed the TW Biotechs industry which returned 2% over the past year.
Return vs Market: 6794 underperformed the TW Market which returned 29% over the past year.
Price Volatility
| 6794 volatility | |
|---|---|
| 6794 Average Weekly Movement | 2.8% |
| Biotechs Industry Average Movement | 4.5% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6794 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6794's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | n/a | www.unicocell.com |
UnicoCell Biomed Co., Ltd. engages in the research and development of stem cell drugs, cell therapy technology, and regenerative medical services in Taiwan. It develops ELIXCYTE, which is in Phase 2 clinical trials for the treatment of osteoarthritis and chronic kidney disease. The company offers UnicoVial, a cryotube and drug container for cell therapy products, as well as provides testing services.
UnicoCell Biomed Co., Ltd. Fundamentals Summary
| 6794 fundamental statistics | |
|---|---|
| Market cap | NT$4.34b |
| Earnings (TTM) | -NT$96.03m |
| Revenue (TTM) | NT$29.08m |
149.4x
P/S Ratio-45.2x
P/E RatioIs 6794 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6794 income statement (TTM) | |
|---|---|
| Revenue | NT$29.08m |
| Cost of Revenue | NT$10.05m |
| Gross Profit | NT$19.03m |
| Other Expenses | NT$115.05m |
| Earnings | -NT$96.03m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.64 |
| Gross Margin | 65.43% |
| Net Profit Margin | -330.22% |
| Debt/Equity Ratio | 0% |
How did 6794 perform over the long term?
See historical performance and comparison